Thyroid blood flow in inferior thyroid artery as predictor for increase in levothyroxine dosage during pregnancy in women with Hashimoto's thyroiditis - a retrospective study.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
05 Jul 2019
Historique:
received: 06 09 2018
accepted: 30 06 2019
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 15 1 2020
Statut: epublish

Résumé

We examined whether inferior thyroid artery peak systolic velocity (ITA-PSV) predicts an increase in levothyroxine (LT4) dosage in pregnant women with Hashimoto's thyroiditis. Twenty-two women with Hashimoto's thyroiditis who were planning and later achieved pregnancy or confirmed as pregnant were enrolled in this retrospective longitudinal observational study. ITA-PSV and thyroid volume were measured using ultrasonography. Serum concentrations of free thyroxine (F-T4), free triiodothyronine (F-T3), and thyroid stimulating hormone (TSH) were simultaneously determined. We adjusted LT4 dosage to maintain serum TSH at < 2.5 μIU/mL (1st trimester) and later at < 3 μIU/mL (2nd, 3rd trimester). Eighteen patients (81.8%) required an increase in LT4 dosage during pregnancy, of whom 7 (31.8%) required an increase ≥50 μg. Multivariable regression analysis showed that TSH (β = 0.507, p = 0.008) and ITA-PSV (β = - 0.362, p = 0.047), but not thyroid volume, F-T4, or F-T3, were independently associated with increased LT4 dosage. Receiver-operating characteristic analysis for predicting an increase in LT4 ≥ 50 μg/day showed that the area under the curve (0.905) for ITA-PSV with TSH was not significantly increased (p = 0.123) as compared to that (0.743) for TSH alone, whereas integrated discrimination improvement was significantly increased (27.9%, p = 0.009). In pregnant patients with Hashimoto's thyroiditis, ITA-PSV was a significant predictor of increase in LT4 dosage independent of TSH level, while ITA-PSV plus TSH showed significantly improved predictability as compared to TSH alone. These results suggest that ITA-PSV reflects residual thyroid function and is useful for evaluating the need for increased thyroid hormone production in pregnant patients with Hashimoto's thyroiditis.

Sections du résumé

BACKGROUND BACKGROUND
We examined whether inferior thyroid artery peak systolic velocity (ITA-PSV) predicts an increase in levothyroxine (LT4) dosage in pregnant women with Hashimoto's thyroiditis.
METHODS METHODS
Twenty-two women with Hashimoto's thyroiditis who were planning and later achieved pregnancy or confirmed as pregnant were enrolled in this retrospective longitudinal observational study. ITA-PSV and thyroid volume were measured using ultrasonography. Serum concentrations of free thyroxine (F-T4), free triiodothyronine (F-T3), and thyroid stimulating hormone (TSH) were simultaneously determined. We adjusted LT4 dosage to maintain serum TSH at < 2.5 μIU/mL (1st trimester) and later at < 3 μIU/mL (2nd, 3rd trimester).
RESULTS RESULTS
Eighteen patients (81.8%) required an increase in LT4 dosage during pregnancy, of whom 7 (31.8%) required an increase ≥50 μg. Multivariable regression analysis showed that TSH (β = 0.507, p = 0.008) and ITA-PSV (β = - 0.362, p = 0.047), but not thyroid volume, F-T4, or F-T3, were independently associated with increased LT4 dosage. Receiver-operating characteristic analysis for predicting an increase in LT4 ≥ 50 μg/day showed that the area under the curve (0.905) for ITA-PSV with TSH was not significantly increased (p = 0.123) as compared to that (0.743) for TSH alone, whereas integrated discrimination improvement was significantly increased (27.9%, p = 0.009).
CONCLUSIONS CONCLUSIONS
In pregnant patients with Hashimoto's thyroiditis, ITA-PSV was a significant predictor of increase in LT4 dosage independent of TSH level, while ITA-PSV plus TSH showed significantly improved predictability as compared to TSH alone. These results suggest that ITA-PSV reflects residual thyroid function and is useful for evaluating the need for increased thyroid hormone production in pregnant patients with Hashimoto's thyroiditis.

Identifiants

pubmed: 31277608
doi: 10.1186/s12884-019-2389-1
pii: 10.1186/s12884-019-2389-1
pmc: PMC6612150
doi:

Substances chimiques

Biomarkers 0
Thyroxine Q51BO43MG4

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

232

Références

Eur J Endocrinol. 1999 May;140(5):452-6
pubmed: 10229913
N Engl J Med. 1999 Aug 19;341(8):549-55
pubmed: 10451459
Thyroid. 2002 Jan;12(1):63-8
pubmed: 11838732
N Engl J Med. 2004 Jul 15;351(3):241-9
pubmed: 15254282
Obstet Gynecol. 2005 Feb;105(2):239-45
pubmed: 15684146
Clin Endocrinol (Oxf). 2005 Dec;63(6):657-62
pubmed: 16343100
Biomed Pharmacother. 2007 Sep;61(8):472-6
pubmed: 17420111
Thyroid. 2009 Mar;19(3):269-75
pubmed: 19265498
Biomed Pharmacother. 2010 Feb;64(2):113-7
pubmed: 20006462
Thyroid. 2010 Oct;20(10):1175-8
pubmed: 20860419
Thyroid. 2011 Oct;21(10):1081-125
pubmed: 21787128
J Clin Endocrinol Metab. 2012 Aug;97(8):2543-65
pubmed: 22869843
N Engl J Med. 1990 Jul 12;323(2):91-6
pubmed: 2359428
Autoimmun Rev. 2014 Apr-May;13(4-5):391-7
pubmed: 24434360
N Engl J Med. 2017 Jun 29;376(26):2556-2565
pubmed: 28657873
Obstet Gynecol. 1993 Mar;81(3):349-53
pubmed: 8437784
J Endocrinol Invest. 1995 Dec;18(11):857-61
pubmed: 8778158
J Clin Endocrinol Metab. 1996 Sep;81(9):3257-60
pubmed: 8784079

Auteurs

Masafumi Kurajoh (M)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. m1155129@med.osaka-cu.ac.jp.

Akiyo Yamasaki (A)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Toshiki Nagasaki (T)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Yuki Nagata (Y)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Shinsuke Yamada (S)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Yasuo Imanishi (Y)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Masanori Emoto (M)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Kanae Takahashi (K)

Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.

Kouji Yamamoto (K)

Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.

Ayumi Shintani (A)

Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.

Masaaki Inaba (M)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH